Drs. Georg Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study
From EHA 2026, Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the phase 3 FRONTMIND study, a randomised, double-blind, placebo-controlled study that evaluated
EHA 2026
Lymphoma
Aggressive B-Cell Lymphomas
Video Interviews
Cellular Therapy
Lymphoma
Post-transplantation outcomes have improved for Hodgkin lymphoma
The improved post-transplantation outcomes are likely due to the introduction of novel therapeutic agents, alongside advances in donor selection, conditioning regimens, and graft-versus-host
Leukemia
Chronic Lymphocytic Leukemia
News
Pathways & Perspectives with William Wierda, MD, PhD
William Wierda, MD, PhD, is a professor of medicine and center medical director for the Department of Leukemia, Division of Cancer Medicine at
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
How can trispecifics be integrated with CELMoDs in myeloma treatment?
The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how
EHA 2026
Trending now
Myelodysplastic Syndromes
News
Video Interviews
Dr. Rami Komrokji on the latest in MDS updates
From EHA 2026, Dr. Komrokji shares the latest research in MDS, and his thoughts on what is next in the field.
SOHO 2026
Trending now
News
Young Investigator Program
Meet SOHO 2026 YIP recipient: Maria Felix Torres, MD
During her residency in the United States, Dr. Torres became even more intrigued by the field. “I was able to see the impact
Multiple Myeloma
News
FDA accepts NDA for mezigdomide combo in relapsed or refractory myeloma
The US Food and Drug Administration has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients
News
Society Updates
SOHO announces launch of 2nd podcast focused on education titled, ‘SOHO Spotlight’
The society is excited to announce the first episode of its educational podcast, SOHO Spotlight.
Focus on CELMoDs
Past Roundtable Discussions
Multiple Myeloma
Roundtable Discussions
Video Interviews
What are the distinguishing features of CELMoDs?
In this roundtable discussion on myeloma and CELMoDs, the panel discuss mechanism of action, overcoming drug resistance, and other distinguishing features of this